Lu-177 PSMA Therapy Not Available in Your Country? How International Patients Get Treatment in India

Lu-177 PSMA Therapy Not Available in Your Country? How International Patients Get Treatment in India

If you have metastatic castration-resistant prostate cancer (mCRPC) and your doctor has mentioned Lu-177 PSMA therapy - or the brand name Pluvicto - you may have hit a roadblock. This therapy is approved in the United States and parts of Europe, but it is not available in most countries. Men in the Gulf states, much of Africa, South Asia, and Southeast Asia have no access at home. Even where the therapy exists, costs and wait times can be too high. Many international patients with PSMA-positive mCRPC now travel to India for treatment - often at a fraction of the cost in the US.

This article is for patients on the PSMA prostate cancer track. If you have a neuroendocrine tumor, a separate article covers PRRT (peptide receptor radionuclide therapy) with Lu-177 DOTATATE.

Why Is Lu-177 PSMA Therapy Hard to Find Outside the US and Europe?

Lu-177 PSMA therapy works by attaching a radioactive molecule to a protein called PSMA (prostate-specific membrane antigen). Most prostate cancer cells have high amounts of PSMA on their surface. The therapy sends radiation directly to those cells, no matter where they have spread in the body.

The US FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto) in March 2022 for adults with PSMA-positive mCRPC who had already received androgen receptor pathway therapy and taxane-based chemotherapy. That approval was based on the VISION trial, which showed a median overall survival of 15.3 months with the therapy versus 11.3 months with standard care alone. In March 2025, the FDA also expanded the indication for patients who have completed prior androgen receptor pathway therapy but may not yet need chemotherapy, based on the PSMAfore trial, as reviewed by the Prostate Cancer Foundation.

But approval in one country does not make a therapy available everywhere. Each country requires its own regulatory process, which takes years. The supply chain for radioactive medicines also makes it harder. Lutetium-177 breaks down quickly after production. A vial made on Monday loses much of its strength by the following week. You cannot store or ship doses the way you ship a tablet. Production around the world is still catching up with demand - even in the United States, patients have waited several months since the drug launched.

For patients in Nigeria, Kenya, Bangladesh, Nepal, Sri Lanka, Oman, Iraq, Qatar, Myanmar, and dozens of other countries, there is simply no domestic option. The question is not whether to wait - it is where to travel.

What Makes India Different for This Treatment?

India has one key advantage: it makes lutetium-177 at home. The Board of Radiation and Isotope Technology (BRIT), a unit of India's Department of Atomic Energy, has produced lutetium-177 for medical use for several years. This means hospitals do not depend on imported doses, which brings costs down significantly.

A published analysis in The Lancet Regional Health - Southeast Asia (2024) found that domestically produced 177Lu-PSMA-617 in India costs approximately INR 80,000 for a standard 100 mCi dose, rising to roughly INR 125,000 per cycle when hospital admission and tests are included. Imported doses from European manufacturers at the same centers cost around INR 250,000 per cycle. Using 2024-2026 exchange rates of roughly 85 INR to the USD, that equals about USD 1,500 to USD 3,000 per cycle - much lower than US list prices.

India also has long experience in nuclear medicine. Major centers in Delhi, Mumbai, Chennai, Hyderabad, and Bengaluru have been doing PSMA-PET imaging and targeted radionuclide therapies for over a decade. Teams at these hospitals include nuclear medicine physicians, radiation oncologists, and medical physicists who work together on every patient case. For international patients, the combination of domestic production, proven clinical expertise, lower cost, and quick access makes India a practical choice when treatment at home is not possible.

How Does Lu-177 PSMA Therapy Cost and Access Compare Across Countries?

Lu-177 PSMA therapy cost and access: India vs US vs GCC and markets without domestic access (2024-2026 estimates) Factor Treatment in India Treatment in US GCC / Africa / South Asia Approx. cost per cycle INR 125,000-250,000 (approx. USD 1,500-3,000; 2024 data) USD 42,500-51,000 per infusion (2022-2026 WAC) Not available domestically in most markets; patients pay for travel plus treatment abroad Approx. full 6-cycle course Approx. USD 9,000-18,000 depending on domestic vs imported Lu-177 USD 255,000+ at list price; insurance covers a variable portion for US patients Not applicable domestically; patients typically seek treatment in India or Europe Regulatory / approval status Approved and produced domestically; available at specialist nuclear medicine centers FDA-approved March 2022; indication expanded March 2025 Not approved in most GCC, African, or South/Southeast Asian markets as of 2025. Typical access wait time Weeks at most established centers; varies with local demand Weeks to several months due to supply and capacity constraints No domestic waiting list; access requires international travel International patient pathway Established; hospitals have dedicated international patient services, visa invitation letters, and teleconsult options Possible but costly and complex without US insurance coverage Most patients from this region travel to India as the most accessible and affordable option

Sources: India cost data from Lancet Regional Health Southeast Asia, 2024. US WAC reference: approximately USD 42,500 per dose at 2022 launch, rising to approximately USD 51,000 per infusion by 2026 per billing code records. Full-course US cost of USD 255,000+ derived from six cycles at list WAC; insurance coverage varies widely. For reference, the Canadian full-course estimate is approximately CAD 122,489 per patient (CADTH Reimbursement Review); US list pricing is higher. GCC and regional approval status requires verification by individual country.

The cost difference between India and the United States is large. A full six-cycle course that may cost USD 255,000 or more at US list prices could be done in India for approximately USD 9,000 to 18,000, depending on whether the center uses domestic or imported lutetium. Even with flights, hotels, and visa fees for multiple trips, the total out-of-pocket cost for an international patient in India is usually far lower than paying on your own in the United States.

Do You Qualify? What International Patients Need to Know About Eligibility

Before planning any travel, the first step is confirming that you are a candidate. Lu-177 PSMA therapy is not appropriate for every patient with prostate cancer. The main eligibility criteria for mCRPC are:

• Your prostate cancer has become castration-resistant - it is growing despite ongoing androgen deprivation therapy.

• A PSMA-PET scan has confirmed that your cancer lesions show adequate PSMA expression. High uptake on the scan is what makes the targeting molecule effective.

• You have had prior treatment with at least one androgen receptor pathway inhibitor (such as enzalutamide or abiraterone). Depending on the treatment sequence your team is following, prior taxane-based chemotherapy may also be required.

• Your blood counts, liver function, and kidney function are at levels that can safely handle the therapy.

If you need a PSMA-PET scan, many Indian centers can arrange one when you arrive as part of your initial workup. In other cases, having the scan done at home before you travel means you arrive with results, which shortens your first trip considerably. For a full guide to what tests and scans are needed before starting, see What Blood Tests and Scans Do You Need Before Lu-177 PSMA Treatment.

Some patients who travel may turn out not to be eligible. If your PSMA-PET shows low expression, or if your kidney function does not meet the threshold, the treating team will tell you what other options exist. Before you book any flights, having your existing records reviewed remotely should be done first. You can consult the Art of Healing Cancer team before traveling for treatment - a remote eligibility review based on your scans and history can help you understand whether the trip makes clinical sense before you commit to it.

What Does the Patient Journey Look Like as an International Patient?

Most international patients follow a path that looks something like this:

1. Remote records review. Share your pathology reports, prior imaging, PSA history, and treatment records with the team in India. This step happens entirely online and typically takes a few days to a week.

2. PSMA-PET scan confirmation. If you have a recent PSMA-PET scan showing positive disease, bring the images. If not, some patients travel to India specifically for the scan as a first step, then discuss results with the nuclear medicine physician before committing to treatment.

3. Teleconsultation. A video call with the nuclear medicine and oncology team reviews your eligibility, explains the cycle plan - typically four to six infusions spaced six to eight weeks apart - and goes over what to expect during and after each session.

4. First treatment cycle. You travel to India. The infusion itself takes approximately three to five hours. You stay in a hospital isolation room for one to two nights because of brief radioactivity after the infusion. After discharge, you receive radiation-safety instructions covering close contact with others and the timing of air travel.

5. Between cycles - stay or return home? Most international patients return home between cycles and travel back for each subsequent infusion. The radiation safety window before air travel is generally around one to two weeks after infusion. Your treating team will give you the specific timeframe based on your post-dose readings.

6. Follow-up imaging. After completing the planned cycles, a repeat PSMA-PET or CT scan is used to assess response. In many cases this imaging can be done at home and reviewed remotely by the Indian team.

For a detailed practical guide covering what to bring, how to prepare medically, and what to expect at each step of your stay, see Planning Your Lu-177 PSMA Treatment Cycle in India: A Medical Preparation and Travel Guide for International Patients.

Managing Costs: What International Patients Should Know

Most international patients pay out of pocket because insurance coverage for treatment abroad is uncommon. Some patients from the Gulf states and Africa have received partial reimbursement through employer health plans or government medical programs, but this varies. Obtain a full written cost estimate from your treatment center before you travel. This should cover the infusion, the hospital stay, any scans needed during that admission, and the follow-up consultation fee. For a side-by-side breakdown of how costs compare between India and the US - including what influences pricing within India itself - see Lu-177 PSMA Therapy Cost in India vs the US: Real Numbers.

What If You Are Not Eligible?

Some patients who seek an assessment will not qualify for Lu-177 PSMA therapy. PSMA expression can be low or absent on imaging. Organ function may not meet the treatment threshold. If you go through a remote review or travel for an assessment and find that this therapy is not appropriate for you, a good nuclear medicine team will help you understand what else you can do. Other systemic therapies, bone-directed options, and clinical trials may apply to your case. The goal of a proper eligibility review is to help you understand the full picture of what is possible.

When to Talk to Your Doctor

Talk to your oncologist if your prostate cancer has continued to grow despite hormone therapy and radioligand therapy has not yet come up in your conversations. Ask specifically whether a PSMA-PET scan is appropriate for your stage and history, and whether your case meets the criteria for an eligibility review. If your doctor is not familiar with radioligand therapy or cannot refer you to a specialist, a second opinion from a nuclear medicine or urologic oncology specialist may be helpful.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.